Leerink initiated coverage of Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) with an Outperform rating and a $5 price target.
New Management As A Catalyst For Growth
Leerink analyst Joseph Schwartz noted several opportunities could create a...
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.